Exclusive: Kevin Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S.

The former OpenAI executive's new lab startup told RuntimeWire it wants to "partner broadly with the frontier labs." Its own site lists OpenAI and Anthropic leaders among its angels.

By · Published

Why it matters

Weil says Warp's early customers are interested in moving drug-discovery work back to the U.S. for commercial, intellectual-property and geopolitical reasons.

AI-generated illustration of a gloved scientist in safety glasses holding a small vial beside a rack of sample tubes and laboratory glassware.

The former OpenAI executive's new lab startup told RuntimeWire it wants to "partner broadly with the frontier labs." Its own site lists OpenAI and Anthropic leaders among its angels.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Reader comments

Conversation for this story loads after sign-in.